Last publication about HIV detection receives huge media coverage

By | 2017, Media, News | No Comments

Major national and international newspapers, radio, tv and online sources have echoed the last research from Bionanomechanics Lab about HIV detection within a week of infection.

The technology, patented by CSIC and licensed to Mecwins, is also being applied in the early detection of some types of cancer.

Due to the huge media coverage of the results, we have selected just a few links for further information:

Developing a biosensor for detecting HIV at first week after infection

By | 2017, News, Publications | No Comments

Early detection of HIV infection is the best way to prevent spread of the disease and to improve the efficiency of the antiretroviral therapy. Nucleic acid amplification tests (NAAT) have become the gold-standard for detecting low-concentrations of the virus in blood. However, these methods are technically demanding and cost-prohibitive in developing countries. Immunoassays are more affordable and can be more easily adapted for point-of-care diagnosis. However, the sensitivity so far of these methods has been too low. The research, published on February 15th in the journal PLOS ONE, reports the development of a sandwich immunoassay that combines nanomechanical and optoplasmonic transduction methods for detecting the HIV-1 capsid antigen p24 in human serum. The immunoreactions take place on the surface of a compliant microcantilever where gold nanoparticles are used as both mechanical and plasmonic labels. The microcantilever acts as both a mechanical resonator and an optical cavity for the transduction of the mechanical and plasmonic signals. The limit of detection of the immunoassay is 10−17 g/mL that is equivalent to one virion in 10 mL of plasma. This is 5 orders of magnitude better than last generation of approved immunoassays and 2 orders of magnitude better than NAAT. This technology meets the demands to be produced en masse at low cost and the capability for miniaturization to be used at the point-of-care.


Schematic representation of the p24 sandwich immunoassay.

(a) The top surface of the cantilever is functionalized with capture antibodies against HIV-1 p24 antigen (top schematic). Antifouling molecules are immobilized on the bottom surface of the cantilever and voids between the antibodies to minimize nonspecific interactions. The cantilever is then immersed in the human serum sample to allow specific binding of p24 to the cantilever surface (middle schematic). Finally, the p24 antigen captured on the cantilever is specifically linked to 100-nm-diameter gold nanoparticles that carry detection antibodies. (b) Scanning electron microscopy image of the silicon microcantilever arrays used in this work. (c). Schematics of the 96-well microtiter plate format, in which the immunoassays were carried out

Source: Kosaka PM, Pini V, Calleja M, Tamayo J (2017) Ultrasensitive detection of HIV-1 p24 antigen by a hybrid nanomechanical-optoplasmonic platform with potential for detecting HIV-1 at first week after infection. PLoS ONE 12(2): e0171899. doi:10.1371/journal.pone.0171899

You can access to the publication in PLOS ONE journal by clicking here.


By | 2017, News | No Comments

Our general director, Dr. Oscar Ahumada and business development manager, Rosalía Calleja have visited India again for a number of commercial actions.

They held an update meeting with the local representative Dr. Anand Dixit (Fourvac). Additionally they took the chance to follow up previous conversations with Solid State Physics Laboratory (SSPL) in Delhi or IIT-Kharagpur. They took also the chance to visit the Central Manufacturing Technology Institute (CMTI) located in Bangalore and give a talk to introduce our latest innovations to the audience.

New field using SCALA opened by research group headed by Prof. Carlos Alemán

By | 2016, News, Publications | No Comments

A group of researchers, Anna Puiggalí-Jou, Luis J. del Valle and Maria M. Pérez-Madrigal, headed by Prof. Carlos Alemán from Universitat Politècnica de Catalunya have just published their results with microcantilevers sensors. The paper “Weighing biointeractions between fibrin (ogen) and clot-binding peptides using microcantilever sensors” published in Journal of Peptide Science examines the biorecognition event between clotted plasma proteins and a tumor-homing pentapeptide, CR(NMe)EKA, by applying a sensing technology based on microcantilevers. The results derived from the different characterization techniques including resonance frequency measurements performed by Mecwins technology (SCALA), reflect the importance of developing emerging technologies suitable for specific medical purposes.



Mecwins in NanoBio&Med 2016

By | 2016, Events, News | No Comments

Barcelona (Spain) – 22 – 24th November, 2016

Mecwins is participating in the next NanoBio&Med2016 to be held in November 22-24th in Barcelona (Spain). Our colleague Dr. Virginia Cebrian from Bioscience Department will be one of the speakers, introducing latest news and innovations of Mecwins technology at the Industrial Forum.

nanobiomed2016The NanoBio&Med conference is a perfect place to present the most recent international developments in the field of Nanobiotechnology and Nanomedicine. As organizers claim in the website of the conference “the discussion in recent advances, difficulties and breakthroughs will be at his higher level”. It will be our second year participating in the event so we can confirm such assertion.

Further information about the event by clicking here

New granted patent

By | 2016, News | No Comments

It has been granted a patent which is being developed at Bionanomechanics Lab from IMM-CSIC (InES2553027_patente_biodeteccionstituto de Microelectrónica de Madrid) by the research group led by Dr. Javier Tamayo and Dr. Montse Calleja.

The invention relates to a System for biodetection applications, which comprises two basic elements, a substrate having a functionalised surface, and a nanoparticle, and which can strengthen the plasmonic effect of the nanoparticle. The invention also relates to a bio-sensor that includes said system, and to the method for detecting and quantifying a target analyte selected in a sample using said system. The invention further relates to a device that can detect the strengthened opto-plasmonic effect of the nanoparticles using the system according to the invention, or combine the detection of said opto-plasmonic effect with the analysis of the changes in the mechanical characteristics of the substrate.


Mecwins project “NANO-PROST” will get more than 700K EUR financial aid under RETOS program

By | 2016, News | No Comments


Mecwins in collaboration with Bionanomechanics Lab from IMM-CSIC (Instituto de Microelectrónica de Madrid) and Advanced Photonic and Biofunctional Materials Group from UAM (Universidad Autónoma de Madrid) will carry out a project to develop ultrasensitive technology for the diagnosis of prostate cancer.

This project, called “NANO-PROST”, will get more than 700K EUR financial aid from the Ministry of Economy and Competitiveness under the “RETOS” program for the period 2016-2018.



Mecwins in Biospain 2016

By | 2016, Events, News | No Comments

Bilbao (Spain) – 28th – 30th September, 2016

Mecwins is participating in the next 8th International Meeting on Biotechnology (Biospain 2016) to be held in September 28th – 30th in Bilbao (Spain). Mecwins will attend this conference along with other companies participated in the CRB Bio II Fund managed by our investor CRB Inverbío, silver sponsor at this conference.

BIOSPAINBiospain2016_OA is the largest biotech event organized by a national bioindustry association in Europe and one of the largest in the world by the number of one-to-one meetings (+3.300) and companies participating (+850). 34% of our delegates came from outside of Spain.

BIOSPAIN is organized by ASEBIO, the Spanish Bioindustry Association and each edition is co-organized by a local institution from the host city/region. On the 2016 edition, Biospain is co-organized by the Basque Government through the SPRI, the Basque Business Development Agency.

Further information about the event by clicking here